Introduction - Scabies is a contagious parasitic infection that is usually mild; however, delays in diagnosis and treatment can cause significant difficulties for patients and their families, as well as pose a risk of secondary transmission. Following numerous reports suggesting a resurgence of scabies in France, we analyzed various available indicators. Method - Voluntary and mandatory reports to public health agencies and sales figures for scabies treatments were examined for the period from 1999 to 2010 in France. Results - Reports to public health agencies suggest an increase in the number of scabies cases in the community and in healthcare facilities. Regional and national sales of scabicides increased. Nationwide, between 2005 and 2009, sales rose from 283 to 402 bottles per 100,000 people per year (+10% per year) for benzyl benzoate and from 216 to 495 treatments per 100,000 people per year (+22%) for ivermectin. These data allow us to estimate the incidence in France at a minimum of 328 cases of scabies per 100,000 people per year. Discussion - The interpretation of the data is discussed, particularly the biases related to reporting practices and the methods of treating cases and their contacts. Nevertheless, the overall information gathered indicates a real increase in the incidence of scabies in France. This finding leads us to recommend increased awareness among the public, clinicians, and public health partners to ensure early diagnosis and treatment.